Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAR 502 First-in-Human Study
NCT05203367Phase 1Withdrawn
- Sponsor
- BAR Pharmaceuticals s.r.l.
- Start
- Nov 2022
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing BAR 502 with Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Assessment of physical examination at Day 8 and 3 more. Planned start Nov 2022; status: withdrawn.
02
Drugs
BAR502
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05203367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203367.